CSIMarket
 
Avidity Biosciences Inc   (RNA)
Other Ticker:  
 
 
Price: $14.0400 $-0.50 -3.439%
Day's High: $14.57 Week Perf: -0.99 %
Day's Low: $ 13.73 30 Day Perf: 38.19 %
Volume (M): 502 52 Wk High: $ 25.38
Volume (M$): $ 7,048 52 Wk Avg: $10.83
Open: $14.57 52 Wk Low: $4.82



 Market Capitalization (Millions $) 1,040
 Shares Outstanding (Millions) 74
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -202
 Cash Flow (TTM) (Millions $) -58
 Capital Exp. (TTM) (Millions $) 4

Avidity Biosciences Inc
Avidity Biosciences Inc is a biotechnology company focused on the development of antibody-based therapeutics. Using its proprietary AOC technology, the company aims to create novel therapies that can address a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Avidity Biosciences combines the high specificity of antibodies with the precision of small molecules to deliver therapeutics that can efficiently target specific cells or tissues. By leveraging its innovative platform, the company aims to revolutionize the treatment of various diseases and improve patient outcomes.


   Company Address: 10578 Science Center Drive San Diego 92121 CA
   Company Phone Number: 401-7900   Stock Exchange / Ticker: NASDAQ RNA
   RNA is expected to report next financial results on February 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Avidity Biosciences Inc

Breaking Records: Avidity Biosciences Inc. Surpasses Revenue Expectations in Q3 2023, but Profitability Remains Elusive

The stock market is a constantly evolving entity, filled with ups and downs, triumphs and setbacks. It is through this rollercoaster that investors strive to find the next big opportunity, the hidden gem that will secure their financial future. Avidity Biosciences Inc may just be that diamond in the rough.
Although their recent financial numbers may not be glowing, there is hope on the horizon. Despite a loss of $0.71 per share in the financial third quarter of 2023, Avidity Biosciences Inc saw their revenue increase by an impressive 13.537% compared to the same reporting season a year prior. This growth indicates that the company is heading in the right direction, even if there are obstacles to overcome.

Avidity Biosciences Inc

Avidity Biosciences Inc. Shines with Impressive Single-Digit Top-Line Improvement in Recent Fiscal Period, Reveals Major Pharmaceutical Breakthrough



Avidity Biosciences Inc (Ticker: ABIO), a prominent player in the Major Pharmaceutical Preparations industry, recently released its financial results for the fiscal period of April to June 30, 2023. The company showcased significant improvement, outpacing industry contemporaries, and positioning itself for future growth.
For the aforementioned period, Avidity Biosciences reduced its loss per share to $-0.66, compared to $-0.92 during the same period the previous year. Additionally, the company's Income per Share saw an improvement from $-0.74 in the prior quarter. This demonstrates the company's commitment to enhancing its financial position and signifies a positive direction for investors.

Avidity Biosciences Inc

Avidity Biosciences Inc. Achieves Marvelous Top-line Improvement in First Quarter of 2023 Earnings Season

RNA's Surge in Revenue and Widening Losses Explained
RNA, a well-known biotech company, recently announced its financial results for the January to March 31, 2023 period. The company experienced a surge in revenue by 24.401%, amounting to $2.23 million. This growth in revenue is impressive and indicates that RNA has been able to capitalize on market opportunities and leverage its competitive strengths. However, investors need to understand that this growth came from a relatively low base, and may not be sustainable in the long term.
At the same time, RNA's losses have widened to $-0.74 per share, compared to the previous year's similar quarter. This may cause concern among investors who are fearful of the company's ability to maintain profitability. It is important to note that RNA continues to invest in research and development, which could account for the widening loss. This investment may not necessarily translate into immediate results, but could pay off in the long-term for the company.






 

Avidity Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com